Previous 10 |
home / stock / ate:cc / ate:cc news
- Patent application filed for improved formulation; strengthens IP protection to 2042 - Anticipated benefits include faster onset of action, lower doses - Phase II molar study no longer required; Phase II bunionectomy study on track for H1 2023 A...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”...
- Otenaproxesul demonstrated efficacy in acute pain clinical study conducted in the UK in 2019 Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target infl...
- Phase II acute pain program to initiate in September - Ended quarter with $50 million in cash and equivalents, providing over two years of runway Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide pla...
- Phase II acute pain program to initiate in early calendar Q4 2022 - Ended year with $55 million in cash and equivalents, providing over two years of runway Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sul...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the " Company "), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “ Warrant Extensio...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair o...
- $6.5 million all-cash transaction, including milestone payments - Enables exclusive focus on drug pipeline Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer ...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference b...
News, Short Squeeze, Breakout and More Instantly...
Antibe Therapeutics Inc. Company Name:
ATE:CC Stock Symbol:
TSXC Market:
Antibe Therapeutics Inc. Website:
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Company’s request for an extension of its previously announced stay of proceedings under the Companies’ Creditors Arrangement Act (the “ CCAA ”...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“ Stay ”) under the Companies’ Creditors Arrangement Act (the “ ...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Compan...